Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

Receptor Agonist ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial

Journal of Dermatological Treatment ◽

10.1080/09546634.2020.1826392 ◽

2020 ◽

pp. 1-7

Author(s):

Lu Lin ◽

Xiangjin Xu ◽

Yunjie Yu ◽

Hongjiang Ye ◽

Xiaoqiong He ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

PLoS ONE ◽

10.1371/journal.pone.0228004 ◽

2020 ◽

Vol 15 (1) ◽

pp. e0228004 ◽

Cited By ~ 2

Author(s):

Takeshi Onoue ◽

Motomitsu Goto ◽

Eri Wada ◽

Mariko Furukawa ◽

Takayuki Okuji ◽

...

Keyword(s):

Type 2 Diabetes ◽

Apolipoprotein B ◽

Controlled Trial ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor

Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Obesity Science & Practice ◽

10.1002/osp4.116 ◽

2017 ◽

Vol 3 (3) ◽

pp. 342-351 ◽

Cited By ~ 12

Author(s):

G. S. Carls ◽

R. Tan ◽

J. Y. Zhu ◽

E. Tuttle ◽

J. Yee ◽

...

Keyword(s):

Type 2 Diabetes ◽

Medication Adherence ◽

Real World ◽

Weight Change ◽

Receptor Agonist ◽

Dipeptidyl Peptidase 4 ◽

Glucagon Like Peptide ◽

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Diabetology & Metabolic Syndrome ◽

10.1186/1758-5996-4-36 ◽

2012 ◽

Vol 4 (1) ◽

Cited By ~ 47

Author(s):

Robert Frederich ◽

Robert McNeill ◽

Niklas Berglind ◽

Douglas Fleming ◽

Roland Chen

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Controlled Trial ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Treatment Naïve

Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial

Diabetology International ◽

10.1007/s13340-021-00513-6 ◽

2021 ◽

Author(s):

Fukumi Yoshikawa ◽

Hiroshi Uchino ◽

Tomoko Nagashima ◽

Shuki Usui ◽

Masahiko Miyagi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glycemic Variability ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Prospective Randomized Controlled Trial

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

Journal of Clinical & Translational Endocrinology ◽

10.1016/j.jcte.2014.03.001 ◽

2014 ◽

Vol 1 (2) ◽

pp. 31-37 ◽

Cited By ~ 6

Author(s):

Luc Van Gaal ◽

Elisabeth Souhami ◽

Tianyue Zhou ◽

Ronnie Aronson

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Obese Patients ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Glucagon Like Peptide ◽

Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial

Diabetes Care ◽

10.2337/diacare.27.6.1335 ◽

2004 ◽

Vol 27 (6) ◽

pp. 1335-1342 ◽

Cited By ~ 218

Author(s):

S. Madsbad ◽

O. Schmitz ◽

J. Ranstam ◽

G. Jakobsen ◽

D. R. Matthews

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Acting

Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial

American Journal of Clinical Nutrition ◽

10.3945/ajcn.115.117440 ◽

2015 ◽

Vol 103 (1) ◽

pp. 66-70 ◽

Cited By ~ 46

Author(s):

Sony S Thazhath ◽

Tongzhi Wu ◽

Michelle J Bound ◽

Helen L Checklin ◽

Scott Standfield ◽

...

Keyword(s):

Type 2 Diabetes ◽

Gastric Emptying ◽

Glycemic Control ◽

Controlled Trial ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2019.06.009 ◽

2019 ◽

Vol 154 ◽

pp. 101-115 ◽

Cited By ~ 5

Author(s):

Maria Ida Maiorino ◽

Paolo Chiodini ◽

Giuseppe Bellastella ◽

Lorenzo Scappaticcio ◽

Miriam Longo ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Randomized Controlled Trials ◽

Receptor Agonist ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.

Diabetes ◽

10.2337/db15-0893 ◽

2015 ◽

pp. db150893 ◽

Cited By ~ 7

Author(s):

Sony S. Thazhath ◽

Chinmay S. Marathe ◽

Tongzhi Wu ◽

Jessica Chang ◽

Joan Khoo ◽

...

Keyword(s):

Type 2 Diabetes ◽

Healthy Subjects ◽

Receptor Agonist ◽

Controlled Trial ◽

Small Intestinal Motility ◽

Glucagon Like Peptide ◽

Small Intestinal ◽

Glucagon Like Peptide 1 ◽

Randomised Controlled